Bladder Cancer (Oncology) - Drugs in Development, 2021

November 2021 | 2564 pages | ID: B36498FF8D2EEN
Global Markets Direct

Abstracts

Bladder Cancer (Oncology) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bladder Cancer - Drugs In Development, 2021, provides an overview of the Bladder Cancer (Oncology) pipeline landscape.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. Risk factors for bladder cancer include smoking, exposure to substances such as rubber, certain dyes and textiles, paint, and hairdressing supplies, diet rich in fried meats and fat, old age, sex and color, certain parasitic infections. Treatment of bladder cancer includes chemotherapy, surgery, biological therapy, and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bladder Cancer - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Bladder Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bladder Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bladder Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 21, 97, 114, 1, 3, 99, 21 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 8, 6, 1, 17 and 3 molecules, respectively.

Bladder Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Bladder Cancer (Oncology).
• The pipeline guide reviews pipeline therapeutics for Bladder Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Bladder Cancer (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Bladder Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Bladder Cancer (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Bladder Cancer (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Bladder Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Bladder Cancer - Overview
Bladder Cancer - Therapeutics Development
Bladder Cancer - Therapeutics Assessment
Bladder Cancer - Companies Involved in Therapeutics Development
Bladder Cancer - Drug Profiles
Bladder Cancer - Dormant Projects
Bladder Cancer - Discontinued Products
Bladder Cancer - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Bladder Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021 .
Number of Products by Stage and Molecule Type, 2021 .
Bladder Cancer - Pipeline by 4C Biomed Inc, 2021 .
Bladder Cancer - Pipeline by 4D Pharma Plc, 2021
Bladder Cancer - Pipeline by 4SC AG, 2021 .
Bladder Cancer - Pipeline by Aadi Bioscience Inc, 2021 .
Bladder Cancer - Pipeline by AbbVie Inc, 2021 .
Bladder Cancer - Pipeline by Abivax SA, 2021
Bladder Cancer - Pipeline by Adaptimmune Therapeutics Plc, 2021
Bladder Cancer - Pipeline by ADC Therapeutics SA, 2021 .
Bladder Cancer - Pipeline by Advaxis Inc, 2021
Bladder Cancer - Pipeline by Advenchen Laboratories LLC, 2021
Bladder Cancer - Pipeline by Agenus Inc, 2021
Bladder Cancer - Pipeline by Alligator Bioscience AB, 2021 .
Bladder Cancer - Pipeline by Alphamab Oncology, 2021
Bladder Cancer - Pipeline by Altor Bioscience LLC, 2021 .
Bladder Cancer - Pipeline by Amgen Inc, 2021 .
Bladder Cancer - Pipeline by Amrita Therapeutics, 2021
Bladder Cancer - Pipeline by Andes Biotechnologies, 2021
Bladder Cancer - Pipeline by Angex Pharmaceutical Inc, 2021 .
Bladder Cancer - Pipeline by Apexian Pharmaceuticals Inc, 2021
Bladder Cancer - Dormant Projects, 2021
Bladder Cancer - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Bladder Cancer, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021